Innovation Endeavors’ Joel Dudley on growing interest in life sciences with new fund — and why he hates ‘techbio’

Co-found­ed by for­mer Google CEO Er­ic Schmidt, tech ven­ture cap­i­tal firm In­no­va­tion En­deav­ors an­nounced a new $630 mil­lion fund Thurs­day — but “ex­pect life sci­ences and health­care to rep­re­sent a ma­jor por­tion of the fund,” part­ner Joel Dud­ley told End­points News.

An in­vestor in Uber and SoFi, In­no­va­tion En­deav­ors has been in­creas­ing­ly in­volved in the biotech space over the past few years. It has put mon­ey in­to com­pa­nies like Eikon Ther­a­peu­tics and Zymer­gen — which was bought by Gink­go Bioworks in 2022 fol­low­ing a ma­jor im­plo­sion — and more re­cent­ly, Think Bio­science and Bi­oLoomics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.